Daptomycin-Nonsusceptible, Vancomycin-Intermediate, Methicillin-Resistant Staphylococcus aureus Endocarditis. Issue 2 (2012)

• Record Type: Journal Article
• Authors: Yu, Ryan; Dale, Suzanne E; Yamamura, Deborah; Stankus, Vida; Lee, Christine
• Is Part Of: Canadian journal of infectious diseases & medical microbiology =. Volume 23:Issue 2(2012)
• Page Start: e48
• Page End: e50
• Publication Date: 2012
• Subjects: Daptomycin nonsusceptible -- Endocarditis -- Methicillin-resistant Staphylococcus aureus -- Vancomycin intermediate resistance; Communicable diseases -- Periodicals; Infection -- Periodicals; Communicable diseases; Infection; Communicable Diseases; Communicable Disease Control; Electronic journals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.9
• DOI: 10.1155/2012/138470
• Languages: English
• ISSNs: 1712-9532

Abstract

Abstract : Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent. To our knowledge, the present report describes the first Canadian case of daptomycin-nonsusceptible, vancomycin-intermediate S aureus infection.